<DOC>
	<DOCNO>NCT01208233</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability PF-03049423 follow multiple dose administration subject ischemic stroke . The study also evaluate efficacy PF-03049423 , relative placebo , subject ischemic stroke follow 90 day therapy . The study also explore relationship PF-03049423 concentration blood pressure .</brief_summary>
	<brief_title>Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke</brief_title>
	<detailed_description>The interim analysis POC study A9541004 demonstrate futility , study stop 6th November 2013 . There signal serious safety concern .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Diagnosis ischemic stroke onset within 72 hour prior start study agent administration , male female . Supratentorial ischemic stroke involve cortex document neurological exam confirm MRI . Stroke involve upper extremity . Subjects receive thrombolytic therapy may enrol use antiplatelet acceptable . Any severe acute chronic medical psychiatric condition besides stroke . Women child bear potential . Uncontrolled hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Phase 2 Ischemic stroke Safety efficacy</keyword>
</DOC>